PMID- 36881187
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230918
IS  - 2730-6011 (Electronic)
IS  - 2730-6011 (Linking)
VI  - 14
IP  - 1
DP  - 2023 Mar 7
TI  - Nonconvulsive status epilepticus characteristics in glioma patients: a 
      retrospective study.
PG  - 30
LID - 10.1007/s12672-023-00632-3 [doi]
LID - 30
AB  - PURPOSE: Epilepsy is a common complication of gliomas. The diagnosis of 
      nonconvulsive status epilepticus (NCSE) is challenging because it causes impaired 
      consciousness and mimics glioma progression. NCSE complication rate in the 
      general brain tumor patient population is approximately 2%. However, there are no 
      reports focusing on NCSE in glioma patient population. This study aimed to reveal 
      the epidemiology and features of NCSE in glioma patients to enable appropriate 
      diagnosis. METHODS: We enrolled 108 consecutive glioma patients (45 female, 63 
      male) who underwent their first surgery between April 2013 and May 2019 at our 
      institution. We retrospectively investigated glioma patients diagnosed with 
      tumor-related epilepsy (TRE) or NCSE to explore disease frequency of TRE/NCSE and 
      patient background. NCSE treatment approaches and Karnofsky Performance Status 
      Scale (KPS) changes following NCSE were surveyed. NCSE diagnosis was confirmed 
      using the modified Salzburg Consensus Criteria (mSCC). RESULTS: Sixty-one out of 
      108 glioma patients experienced TRE (56%), and five (4.6%) were diagnosed with 
      NCSE (2 female, 3 male; mean age, 57 years old; WHO grade II 1, grade III 2, 
      grade IV 2). All NCSE cases were controlled by stage 2 status epilepticus 
      treatment as recommended in the Clinical Practice Guidelines for Epilepsy by the 
      Japan Epilepsy Society. The KPS score significantly decreased after NCSE. 
      CONCLUSION: Higher prevalence of NCSE in glioma patients was observed. The KPS 
      score significantly decreased after NCSE. Actively taking electroencephalograms 
      analyzed by mSCC may facilitate accurate NCSE diagnosis and improve the 
      activities of daily living in glioma patients.
CI  - (c) 2023. The Author(s).
FAU - Kaneoka, Azumi
AU  - Kaneoka A
AUID- ORCID: 0000-0003-0897-6254
AD  - Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, 
      Bunkyo-ku, Tokyo, Japan.
FAU - Fujimoto, Satoka Hashimoto
AU  - Fujimoto SH
AUID- ORCID: 0000-0003-2374-3002
AD  - Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, 
      Bunkyo-ku, Tokyo, Japan. satoka.hashimoto@gmail.com.
FAU - Tamura, Kaoru
AU  - Tamura K
AUID- ORCID: 0000-0002-7943-5458
AD  - Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, 
      Bunkyo-ku, Tokyo, Japan.
FAU - Inaji, Motoki
AU  - Inaji M
AUID- ORCID: 0000-0002-6759-5729
AD  - Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, 
      Bunkyo-ku, Tokyo, Japan.
FAU - Maehara, Taketoshi
AU  - Maehara T
AUID- ORCID: 0000-0001-6804-4665
AD  - Department of Neurosurgery, Tokyo Medical and Dental University, 1-5-45 Yushima, 
      Bunkyo-ku, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230307
PL  - United States
TA  - Discov Oncol
JT  - Discover oncology
JID - 101775142
PMC - PMC9992690
OTO - NOTNLM
OT  - Epilepsy
OT  - Glioma
OT  - Modified Salzburg Consensus Criteria (mSCC)
OT  - Nonconvulsive status epilepticus (NCSE)
COIS- The authors have no relevant financial or non-financial interests to disclose.
EDAT- 2023/03/08 06:00
MHDA- 2023/03/08 06:01
PMCR- 2023/03/07
CRDT- 2023/03/07 11:16
PHST- 2022/12/27 00:00 [received]
PHST- 2023/02/17 00:00 [accepted]
PHST- 2023/03/07 11:16 [entrez]
PHST- 2023/03/08 06:00 [pubmed]
PHST- 2023/03/08 06:01 [medline]
PHST- 2023/03/07 00:00 [pmc-release]
AID - 10.1007/s12672-023-00632-3 [pii]
AID - 632 [pii]
AID - 10.1007/s12672-023-00632-3 [doi]
PST - epublish
SO  - Discov Oncol. 2023 Mar 7;14(1):30. doi: 10.1007/s12672-023-00632-3.